Role of traditional Chinese medicine (Acupuncture) in reducing blood pressure

EFFECT OF INTEGRATED ACUPUNCTURE ON THE SYSTOLIC AND DIASTOLIC BLOOD PRESSURE, QUALITY OF LIFE, HRV INDICES AND DEPRESSION, STRESS AND ANXIETY LEVELS OF THE INDIVIDUALS WITH BORDERLINE AND STAGE 1 HYPERTENSION: A RANDOMISED PLACEBO CONTROLLED STUDY

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/04/041743

Enrollment

Registered

2022-04-08

Start date

Unknown

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: INTEGRATED ACUPUNCTURE: 10 DAYS OF ACUPUNCTURE ALONGWITH YOGA AND NATUROPATHY INTERVENTION Control Intervention1: SHAM ACUPUNCTURE: 10 DAYS OF SHAM ACUPUNCTURE ALONGWITH YOGA AND NATURO

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged between 30 and 60 years, male and female, both taking and not taking antihypertensive drugs. Patients who meet the diagnostic criteria of Borderline and Stage I hypertension according to (JNC-7 and WHO/ISH criteria Border line and stage I) Systolic blood pressure 159>=(SBP) >=130 and/or diastolic blood pressure 99>=(DBP) >=85 . Patients who are diagnosed as Liver-yang excess (common symptoms include headache, feeling of head distension and vertigo, blurred vision, irritability, anger, tinnitus, insomnia). Patients who have a good understanding of the trial and willing to comply with trial protocol. Informed consent form must be signed by patient or lineal relative.

Exclusion criteria

Exclusion criteria: Patients who have been diagnosed as stage II hypertension and secondary hypertension. Patients with accompanying other severe medical conditions who may be not safe to join our study. Patients with a chronic disease which might not be suitable for the trial e.g: epilepsy, patients under any psychotic medications. Pregnant women or women in lactation. Patients who currently are participating in other clinical trials. Patients treated with acupuncture during the previous three months.

Design outcomes

Primary

Measure	Time frame
BLOOD PRESSURETimepoint: AT BASELINE (DAY 1) END OF ACUPUNCTURE (DAY 10) FOLLOW UP (DAY 40)	—

Secondary

Measure	Time frame
DEPRESSION, ANXIETY AND STRESS LEVELSTimepoint: AT BASELINE (DAY 1) END OF ACUPUNCTURE (DAY 10) FOLLOW UP (DAY 40);HRV INDICESTimepoint: AT BASELINE (DAY 1) END OF ACUPUNCTURE (DAY 10);QUALITY OF LIFETimepoint: AT BASELINE (DAY 1) END OF ACUPUNCTURE (DAY 10) FOLLOW UP (DAY 40)	—

Countries

India

Contacts

Public ContactDEEPIKA SINGH

SANT HIRDARAM MEDICAL COLLEGE OF NATUROPATHY AND YOGIC SCIENCES FOR WOMEN

SinghDeepika1193@gmail.com8989507436

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026